A Prospective multicentre, phase 2b randomised controlled double-blind trial, to determine the safety and efficacy of perispinal etanercept on quality of life at 28 days post treatment. 

Lead PI: Professor Vincent Thijs

Participating Australian and New Zealand Sites: Austin Health, Alfred Health, CGM Research Trust

Status: ASTN endorsed, Site selection, Recruiting

No. of Patients Currently Recruited: 40                                No. of Patients Required: 168

All three sites are actively recruiting patients. Site target goal is to recruit 1 patient per week to help meet recruitment target of 168 total. Other advertising/recruitment strategies are also being explored in parallel, to help boost and keep recruitment momentum. 



Related Posts